← All trials
NCT05816057
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2022
- Primary completion
- Dec 30, 2023
- Completion date
- Dec 30, 2024
- First posted
- Apr 18, 2023
- Last posted
- Apr 18, 2023
- Enrollment
- 476
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.